Royal Bank of Canada’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-36,200
| Closed | -$108K | – | 6962 |
|
|
2016
Q3 | $108K | Sell |
36,200
-18,010
| -33% | -$31.2K | ﹤0.01% | 4786 |
|
|
2016
Q2 | $81K | Sell |
54,210
-4,037
| -7% | -$9.23K | ﹤0.01% | 4877 |
|
|
2016
Q1 | $216K | Buy |
58,247
+53,722
| +1,187% | +$333K | ﹤0.01% | 4316 |
|
|
2015
Q4 | $45K | Buy |
+4,525
| New | +$54.5K | ﹤0.01% | 5368 |
|
|
2015
Q3 | – | Sell |
-9,739
| Closed | -$185K | – | 6936 |
|
|
2015
Q2 | $185K | Buy |
+9,739
| New | +$211K | ﹤0.01% | 4430 |
|
|
2015
Q1 | – | Sell |
-162,936
| Closed | -$3.41M | – | 6609 |
|
|
2014
Q4 | $3.41M | Buy |
162,936
+79
| +0% | +$1.99K | ﹤0.01% | 1914 |
|
|
2014
Q3 | $5.44M | Buy |
162,857
+5,539
| +4% | +$172K | ﹤0.01% | 1593 |
|
|
2014
Q2 | $5.05M | Buy |
157,318
+156,918
| +39,230% | +$5.84M | ﹤0.01% | 1650 |
|
|
2014
Q1 | $19K | Buy |
400
+384
| +2,400% | +$22.5K | ﹤0.01% | 5233 |
|
|
2013
Q4 | $1K | Sell |
16
-5,422
| -100% | -$415K | ﹤0.01% | 5863 |
|
|
2013
Q3 | $466K | Buy |
5,438
+5,149
| +1,782% | +$436K | ﹤0.01% | 3428 |
|
|
2013
Q2 | $18K | Buy |
+289
| New | +$15.3K | ﹤0.01% | 5080 |
|
Royal Bank of Canada's AEGR Position: Q4 2016 in Review
Royal Bank of Canada sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 36,200 shares — an estimated $108K sold.
Royal Bank of Canada first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $5.44M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Royal Bank of Canada reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Royal Bank of Canada sold 36,200 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $108K.
- Royal Bank of Canada first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
- Royal Bank of Canada's Aegerion Pharmaceuticals position peaked at $5.44M in Q3 2014.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Royal Bank of Canada's 13F filing for Q4 2016, filed 14 Feb 2017.